Former Galena chief Mark Ahn back in hot water as DOJ levels insider trading charges for consultant work
When Mark Ahn departed troubled Galena Pharmaceuticals back in 2014, he told investors he looking to pursue other “long-held” goals. Turns out one of those goals may allegedly have been peddling stock based on insider info.
The DOJ on Monday charged Ahn, Galena’s former CEO, with two counts of securities fraud after he allegedly bought a biotech’s stock based on nonpublic information about the company’s intent to sell, which he acquired as a consultant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.